Search results
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
Motley Fool via Yahoo Finance· 5 days agoFirst-quarter sales of the blood clot-preventing tablet climbed 9% year over year to $3.7 billion....
Is Viking Therapeutics Stock a Buy on the Dip? | The Motley Fool
The Motley Fool· 2 days agoViking Therapeutics (VKTX -6.57%) is an anomaly of sorts. Despite another underwhelming year for...
Drs. Oz and Roizen: Avoiding the serious risks from online pharmacies
telegraphherald.com· 4 days agoSome even send you drugs without a doctor’s prescription. A report from the IQVIA Institute for Human Data Science says that opioids and ADHD drugs are among the most often ...
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
Zacks via Yahoo Finance· 5 days agoGSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling...
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
Zacks via Yahoo Finance· 2 days agoAnother stock from the same industry, Amgen (AMGN), has gained 0% over the past month. More than a...
Dean Baker, DC Report @ Raw Story
The Raw Story· 3 hours agoHow will our children know they face a crushing debt burden? Of course, they will know because there are a number of well-funded policy shops that will be spewing out endless papers and columns ...
This prescription gummy was designed to treat erectile dysfunction
Fast Company Magazine· 4 days agoIn 2024, erectile dysfunction patients have an abundance of candy-like choices from...
AbbVie's tight grip on Humira market raises concerns about biosimilars
AOL· 1 day agoHumira, which lists for almost $7,000 a month, is the first top-selling drug to compete with a slew of biosimilars, which are close but not exact copies of branded biologic ...
2 No-Brainer Dividend Stocks You Can Buy With $100 in June | The Motley Fool
The Motley Fool· 5 days agoSearching for investments that can outperform the benchmark S&P 500 index often gets wickedly...
Medicare Part D Plans Poorly Cover Adalimumab Biosimilars
Medscape· 2 days agoThis narrow coverage limits the cost-saving potential of these biosimilar competitors, expert said.